AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update Landmark exclusive option and license deal with Takeda for ACI-24.060 with $100 million upfront and additional potent ...

AC Immune SA reported its full-year financial results for 2024, highlighting significant advancements in its pipeline and a landmark partnership with Takeda for the immunotherapy ACI-24.060, which ...

AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate UpdateLandmark exclusive option and license deal with Takeda for ...

ACI-35.030 (JNJ-2056) anti-phospho-Tau (anti-pTau ... Phase 1 clinical trial of TDP-43-PET tracer ACI-19626 in genetic frontotemporal dementia (FTD) is ongoing with initial clinical data expected ...

Journal of Nuclear Medicine March 2025, jnumed.124.268700; DOI: https://doi.org/10.2967/jnumed.124.268700 ...

AC Immune's partner Life Molecular Imaging (LMI) received FDA Fast Track Designation for the Tau positron emission tomography ... Phase 1 clinical trial of TDP-43-PET tracer ACI-19626 in genetic ...

Directly inherited dementia is rare, but in around three in every 10 people with FTD a strong family history of the condition is known. In these cases the cause is likely to be genetic. This is known ...

We rated 160 cat and 169 dog policies on cover ranging from vet fee limits to advertising if your pet goes missing.

Alector is advancing latuzinumab for frontotemporal dementia (FTD) in a fully enrolled Phase ... including amyloid PET, tau PET, CSM CSF and plasma. So this study, has enrolled quite well.

Frontotemporal dementia also called FTD, is a rarer type of dementia caused by a build up of proteins, tau, FUS and TDP-43, in the frontal and temporal lobes of the brain. Dementia is caused by ...

In the study, titled "Sex Differences in Longitudinal Tau-PET in Preclinical Alzheimer Disease: A Meta-Analysis," researchers performed a meta-analysis of longitudinal data from six major aging ...